490 656
Table 1 –
[9_TD$DIFF]
Magnitudes of the joint bounding factor for different combinations of
[1_TD$DIFF]
the
[10_TD$DIFF]
odds of receiving trimodal therapy
[11_TD$DIFF]
vs. radical cystectomy
[12_TD$DIFF]
(OR
TMT-
[13_TD$DIFF]
U
)
[14_TD$DIFF]
and
[5_TD$DIFF]
likelihood of
[15_TD$DIFF]
OS (
[16_TD$DIFF]
HR
OS
[17_TD$DIFF]
-U
)
[18_TD$DIFF]
both
[19_TD$DIFF]
in
presence of unmeasured confounders
Bounding factor
OR = odds of receiving trimodal therapy vs radical cystectomy in presence of unmeasured confounders
5.00
4.00
3.50
3.00
2.50
2.20
2.00
1.80
1.50
1.40
1.30
1.20
1.10
1.00
HR = likelihood of OS in presence of unmeasured confounders
1.00
1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 ) 1.37 ( 1.16 1.59 )
1.10
1.37 ( 1.16 1.59 ) 1.36 ( 1.15 1.58 ) 1.35 ( 1.14 1.57 ) 1.34 ( 1.14 1.56 ) 1.33 ( 1.13 1.55 ) 1.33 ( 1.12 1.54 ) 1.31 ( 1.11 1.53 ) 1.31 ( 1.11 1.52 ) 1.30 ( 1.10 1.51 )
1.30 ( 1.10 1.5 )
1.29 ( 1.09 1.49 ) 1.28 ( 1.08 1.49 ) 1.28 ( 1.08 1.48 ) 1.27 ( 1.08 1.47 )
1.20
1.37 ( 1.16 1.59 ) 1.35 ( 1.14 1.57 ) 1.33 ( 1.13 1.55 ) 1.32 ( 1.12 1.53 ) 1.30 ( 1.10 1.51 )
1.29 ( 1.10 1.5 )
1.27 ( 1.07 1.47 ) 1.26 ( 1.06 1.46 ) 1.25 ( 1.05 1.45 ) 1.23 ( 1.04 1.43 ) 1.22 ( 1.03 1.41 ) 1.21 ( 1.02 1.40 ) 1.20 ( 1.02 1.39 ) 1.19 ( 1.01 1.38 )
1.30
1.37 ( 1.16 1.59 ) 1.34 ( 1.14 1.56 ) 1.32 ( 1.12 1.53 ) 1.30 ( 1.10 1.51 ) 1.28 ( 1.08 1.49 ) 1.26 ( 1.07 1.47 ) 1.23 ( 1.04 1.43 ) 1.21 ( 1.03 1.41 ) 1.20 ( 1.01 1.39 )
1.18 ( 1.00 1.37 ) 1.16 ( 0.98 1.35 ) 1.14 ( 0.97 1.33 ) 1.13 ( 0.96 1.31 ) 1.12 ( 0.95 1.30 )
1.40
1.37 ( 1.16 1.59 ) 1.33 ( 1.13 1.55 ) 1.30 ( 1.10 1.51 ) 1.28 ( 1.08 1.49 ) 1.26 ( 1.07 1.46 ) 1.24 ( 1.05 1.44 ) 1.20 ( 1.01 1.39 )
1.17 ( 0.99 1.36 ) 1.16 ( 0.98 1.34 ) 1.14 ( 0.96 1.32 ) 1.11 ( 0.94 1.29 ) 1.09 ( 0.92 1.27 ) 1.08 ( 0.91 1.25 ) 1.06 ( 0.89 1.23 )
1.50
1.37 ( 1.16 1.59 ) 1.33 ( 1.12 1.54 ) 1.29 ( 1.10 1.50 ) 1.26 ( 1.07 1.47 ) 1.24 ( 1.05 1.44 ) 1.22 ( 1.03 1.41 )
1.17 ( 0.99 1.35 ) 1.14 ( 0.97 1.33 ) 1.12 ( 0.95 1.30 )
1.1 ( 0.93 1.27 )
1.07 ( 0.90 1.24 ) 1.04 ( 0.88 1.21 ) 1.03 ( 0.87 1.19 ) 1.00 ( 0.85 1.17 )
1.60
1.37 ( 1.16 1.59 ) 1.32 ( 1.12 1.54 ) 1.28 ( 1.09 1.49 ) 1.25 ( 1.06 1.45 ) 1.22 ( 1.04 1.42 ) 1.20 ( 1.02 1.39 )
1.14 ( 0.97 1.33 ) 1.11 ( 0.94 1.29 ) 1.09 ( 0.92 1.26 )
1.06 ( 0.9 1.23 )
1.03 ( 0.87 1.19 ) 1.00 ( 0.85 1.16 ) 0.98 ( 0.83 1.14 ) 0.96 ( 0.81 1.11 )
1.80
1.37 ( 1.16 1.59 ) 1.31 ( 1.11 1.53 ) 1.27 ( 1.07 1.47 ) 1.23 ( 1.04 1.43 ) 1.20 ( 1.01 1.39 )
1.17 ( 0.99 1.35 ) 1.10 ( 0.93 1.28 ) 1.07 ( 0.90 1.24 ) 1.04 ( 0.88 1.20 ) 1.00 ( 0.85 1.17 ) 0.96 ( 0.82 1.12 ) 0.94 ( 0.79 1.09 ) 0.91 ( 0.77 1.06 ) 0.88 ( 0.75 1.02 )
2.00
1.37 ( 1.16 1.59 ) 1.31 ( 1.11 1.52 ) 1.26 ( 1.06 1.46 ) 1.21 ( 1.03 1.41 )
1.17 ( 0.99 1.36 ) 1.14 ( 0.97 1.33 ) 1.07 ( 0.90 1.24 ) 1.03 ( 0.87 1.19 ) 1.00 ( 0.84 1.16 ) 0.96 ( 0.81 1.11 ) 0.91 ( 0.77 1.06 ) 0.88 ( 0.75 1.02 ) 0.86 ( 0.73 0.99 ) 0.82 ( 0.70 0.95 )
2.20
1.37 ( 1.16 1.59 ) 1.30 ( 1.10 1.51 ) 1.25 ( 1.05 1.45 )
1.2 ( 1.01 1.39 )
1.16 ( 0.98 1.34 ) 1.12 ( 0.95 1.30 ) 1.04 ( 0.88 1.20 ) 1.00 ( 0.84 1.16 ) 0.96 ( 0.81 1.12 ) 0.92 ( 0.78 1.07 ) 0.87 ( 0.74 1.01 ) 0.84 ( 0.71 0.97 ) 0.81 ( 0.69 0.94 ) 0.77 ( 0.65 0.90 )
2.50
1.37 ( 1.16 1.59 ) 1.30 ( 1.10 1.50 ) 1.23 ( 1.04 1.43 )
1.18 ( 1.00 1.37 ) 1.14 ( 0.96 1.32 ) 1.10 ( 0.93 1.27 ) 1.00 ( 0.85 1.17 ) 0.96 ( 0.81 1.11 ) 0.92 ( 0.78 1.07 ) 0.88 ( 0.74 1.02 ) 0.82 ( 0.70 0.95 ) 0.78 ( 0.66 0.91 ) 0.75 ( 0.64 0.87 ) 0.71 ( 0.60 0.83 )
2.80
1.37 ( 1.16 1.59 ) 1.29 ( 1.09 1.50 ) 1.22 ( 1.04 1.42 )
1.17 ( 0.99 1.35 ) 1.12 ( 0.95 1.30 ) 1.08 ( 0.91 1.25 ) 0.98 ( 0.83 1.14 ) 0.93 ( 0.79 1.08 ) 0.89 ( 0.75 1.03 ) 0.84 ( 0.71 0.98 ) 0.78 ( 0.66 0.91 ) 0.74 ( 0.63 0.86 ) 0.71 ( 0.60 0.82 ) 0.67 ( 0.56 0.77 )
3.00
1.37 ( 1.16 1.59 ) 1.29 ( 1.09 1.49 ) 1.22 ( 1.03 1.41 )
1.16 ( 0.98 1.35 ) 1.11 ( 0.94 1.29 ) 1.07 ( 0.90 1.24 ) 0.96 ( 0.82 1.12 ) 0.91 ( 0.77 1.06 ) 0.87 ( 0.74 1.01 ) 0.82 ( 0.70 0.95 ) 0.76 ( 0.64 0.88 ) 0.72 ( 0.61 0.83 ) 0.69 ( 0.58 0.80 ) 0.64 ( 0.54 0.74 )
3.50
1.37 ( 1.16 1.59 ) 1.28 ( 1.08 1.49 ) 1.21 ( 1.02 1.40 )
1.14 ( 0.97 1.33 ) 1.09 ( 0.92 1.27 ) 1.04 ( 0.88 1.21 ) 0.94 ( 0.79 1.09 ) 0.88 ( 0.75 1.02 ) 0.84 ( 0.71 0.97 ) 0.78 ( 0.66 0.91 ) 0.72 ( 0.61 0.83 ) 0.67 ( 0.57 0.78 ) 0.64 ( 0.54 0.74 ) 0.59 ( 0.50 0.68 )
4.00
1.37 ( 1.16 1.59 ) 1.28 ( 1.08 1.48 ) 1.20 ( 1.02 1.39 )
1.13 ( 0.96 1.31 ) 1.08 ( 0.91 1.25 ) 1.03 ( 0.87 1.19 ) 0.91 ( 0.77 1.06 ) 0.86 ( 0.73 0.99 ) 0.81 ( 0.69 0.94 ) 0.75 ( 0.64 0.87 ) 0.69 ( 0.58 0.80 ) 0.64 ( 0.54 0.74 ) 0.60 ( 0.51 0.70 ) 0.55 ( 0.46 0.64 )
4.50
1.37 ( 1.16 1.59 ) 1.27 ( 1.08 1.48 ) 1.19 ( 1.01 1.38 )
1.12 ( 0.95 1.30 ) 1.07 ( 0.90 1.24 ) 1.01 ( 0.86 1.18 ) 0.90 ( 0.76 1.04 ) 0.84 ( 0.71 0.97 ) 0.79 ( 0.67 0.92 ) 0.73 ( 0.62 0.85 ) 0.66 ( 0.56 0.77 ) 0.61 ( 0.52 0.71 ) 0.57 ( 0.48 0.66 ) 0.52 ( 0.44 0.60 )
5.00
1.37 ( 1.16 1.59 ) 1.27 ( 1.08 1.47 ) 1.19 ( 1.01 1.38 )
1.12 ( 0.95 1.30 ) 1.06 ( 0.89 1.23 ) 1.00 ( 0.85 1.17 ) 0.88 ( 0.75 1.02 ) 0.82 ( 0.70 0.95 ) 0.77 ( 0.65 0.90 ) 0.71 ( 0.60 0.83 ) 0.64 ( 0.54 0.74 ) 0.59 ( 0.50 0.68 ) 0.55 ( 0.46 0.64 ) 0.49 ( 0.42 0.57 )
Columns correspond to increasing imbalance in unmeasured confounders between treatment groups
[7_TD$DIFF]
while rows correspond to increasing adverse effect of unmeasured confounders on OS.
[21_TD$DIFF]
As such, the
[22_TD$DIFF]
present sensitivity
analysis allows
[23_TD$DIFF]
for
[24_TD$DIFF]
testing the treatment effect of trimodal therapy
[11_TD$DIFF]
vs. radical cystectomy in
[8_TD$DIFF]
presence of unmeasured confounders with varying
[25_TD$DIFF]
combination of imbalance between treatment groups and impact on OS. Dark
blue, light blue
[7_TD$DIFF]
and orange areas correspond to a joint bounding factor
[26_TD$DIFF]
– HR of trimodal therapy vs. radical cystectomy in presence of unmeasured confounders with a given combination of
[27_TD$DIFF]
imbalance
[28_TD$DIFF]
(OR
TMT-U
[29_TD$DIFF]
) and
[30_TD$DIFF]
impact
on OS
[31_TD$DIFF]
(HR
OS-U
[32_TD$DIFF]
) – suggestive of a significant,
[33_TD$DIFF]
non-significant and reverse treatment effect, respectively.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 4 8 8 – 4 9 1
490